



ASX & MEDIA RELEASE

29 JULY 2015

NSW GOVERNMENT GRANTS MEDLAB A LICENCE FOR MEDICAL CANNABIS RESEARCH

The New South Wales government has granted a licence for research on medical cannabis to nutritional pharmaceutical company, Medlab Clinical (Medlab), making it one of the first commercial entities in New South Wales.

Medlab operates a certified biologics laboratory facility in Sydney and its research on cannabis will be for therapeutic purposes, including development of an alternative method of administration of cannabis for therapeutic purposes, for example, buccal delivery.

Medlab's research will broadly encompass pain management as well as other medical conditions and for varying age groups.

According to Medlab Clinical CEO, Mr Sean Hall, receiving approval to begin research on cannabis was a big breakthrough and would enable Medlab's research team to begin work in the lab with a view to developing protocols for human clinical trials," Mr Hall said.

"For the past few years we have developed a delivery platform (NanoCelle™) which should provide safe and efficacious dosing. Our aim is to demonstrate clinical usage with minimum risk to patients."

Medlab's research is being led by Professor Luis Vitetta, Medlab Clinical's Director of Medical Research and Adjunct Professor at the University of Sydney Medical School.

The research focus Medlab pursues is the role bacteria in the gastrointestinal tract play in health and disease and its initial research direction with cannabis would be to combine its chemical components with bacteria that relate to pain receptors in the body.

Medlab recently listed on the Australian Securities Exchange after raising over \$6 million in its initial public offer, with funds to be directed to research as well as development of nutraceutical products and medical delivery platforms.

In its bacteria-focused research, Medlab is targeting five health issues - obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management.

Its most advanced work is with obesity and depression where it has begun human trials.

ISSUED FOR: MEDLAB CLINICAL LTD – www.medlab.co

FOR FURTHER INFORMATION: MR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based biotechnology company, with a certified biologics facility in Sydney and sales arms in Australia and California (InMed Technologies). The research focus is on the role bacteria in the gastrointestinal tract play in health and disease, in five health areas: obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. Medlab develops and sells nutraceuticals in the US and Australia to support drug discovery and development of new medicines involving bacteria (pharmacobiotics). Medlab currently has 9 patents pending and 6 in draft, 15 published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.